Sophie de Carne

Affiliated Researcher

I am a postdoc interested in immuno-oncology. My current scientific objective is to understand better the influence of oncogenic RAS signalling on the tumour microenvironment to define the best strategies to tackle RAS-driven cancers. I notably use single-cell multi-omics (CITE-Seq) to characterise human and mouse tumours. 

Displaying 1 - 14 of 14
Last updated : 03 March 2026 03:35

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinoma

Preprint
Authors (24)
bioRxiv
Published
Crick labs/ facilities
Full details

Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumour cells

Preprint
Authors (15)
bioRxiv
Published
Crick labs/ facilities
Full details

Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma

Authors (37)
  • Dhruva Biswas
  • Yun-Hsin Liu
  • Javier Herrero
  • Yin Wu
  • David A Moore
  • Takahiro Karasaki
  • [...]
  • Allan Hackshaw
  • Mariam Jamal-Hanjani
  • Nnennaya Kanu
  • Nicolai Birkbak
  • Charles Swanton
Nature Cancer
Published
Crick labs/ facilities
Full details

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade

Authors (16)
Nature Communications
Published
Crick labs/ facilities
Full details

CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer

Authors (16)
Cancer Research
Published
Crick labs/ facilities
Full details

Genomic-transcriptomic evolution in lung cancer and metastasis

Authors (47)
  • Carlos Martínez-Ruiz
  • James RM Black
  • Clare Puttick
  • Mark S Hill
  • Jonas Demeulemeester
  • Elizabeth Larose Cadieux
  • [...]
  • Peter Van Loo
  • Mariam Jamal-Hanjani
  • TRACERx Consortium
  • Charles Swanton
  • Nicholas McGranahan
Nature
Published
Crick labs/ facilities
Full details

An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations

Authors (26)
Cancer Research
Published
Crick labs/ facilities
Full details